Introduction
The development of vectors that function efficiently both in animal models and in humans is critically important for their use in gene therapy. For transduction of mammalian cells, the majority of gene transfer experiments to date have used viral vectors encoding transgenes under the control of promoter elements derived from viruses. One of the most frequently used promoters in these expression cassettes is that of the human cytomegalovirus (HCMV) immediate early (IE) gene. The HCMV enhancer\promoter directs high levels of transgene expression in a wide variety of cell types (Schmidt et al., 1990 ; Boshart et al., 1985) . The activity of this promoter depends on a series of 17, 18, 19 and 21 bp imperfect repeats the murine CMV (MCMV) IE promoter resulted in an increase in the levels of β-gal produced in murine and rat cells by approximately 5-30-fold compared to levels obtained with the HCMV IE promoter, and levels produced in human cells were the same or greater using the MCMV IE promoter compared to the HCMV IE promoter. Similar results were obtained using a luciferase reporter gene. The MCMV IE promoter, therefore, was able to drive high levels of expression without the pronounced species preferences observed for the HCMV IE promoter. The MCMV IE promoter also directed high levels of expression in vivo, suggesting that Ad vectors carrying the MCMV IE promoter may be more effective than those with the HCMV IE promoter for transgene expression in animal models. (Fickenscher et al., 1989 ; Hunninghake et al., 1989 ; Ghazal et al., 1988 ; Boshart et al., 1985) , some of which bind transcription factors of the NF-κB, cAMP responsive binding protein (CREB) and the nuclear factor-1 families (Niller & Hennighausen, 1991 ; Stamminger et al., 1990 ; Fickenscher et al., 1989 ; Sambucetti et al., 1989 ; Hennighausen & Fleckenstein, 1986) . These repeats occur within the enhancer region which has been localized to k524 to k118 relative to the transcriptional start site of the immediate early gene (Boshart et al., 1985) . Approximately 300 bp of this enhancer sequence (k458 to k118) was sufficient for the direction of high level expression in an enhancer trap assay (Boshart et al., 1985) . This fragment of the HCMV IE enhancer retained the ability to induce expression in a broad host range of cell types including human, mouse and frog cells, although the absolute levels of expression varied considerably between species. We and others have used a fragment of the HCMV IE promoter for transgene expression in adenoviral (Ad) vectors, and have shown that this element provides high levels of expression both in vitro and in vivo ( Bramson et al., 1996 a, b ; Addison et al., 1995 a, b ; Hitt et al., 1995 ; Wilkinson & Akrigg, 1992) .
To further examine the ability of the HCMV IE promoter to drive expression of foreign genes in Ad vectors, we constructed viral vectors with lacZ or luciferase reporter genes under the control of the HCMV IE promoter element from k299 to j72, relative to the transcriptional start site. We have used these Ad vectors to determine whether orientation of the expression cassette within the viral vector has an effect on gene expression, and to examine variations in expression associated with different cell types in vitro. Previous work demonstrated that both human and murine cells infected with Ad vectors encoding either the interleukin-2 (IL-2) or murine interleukin-4 (IL-4) cDNA under control of the HCMV IE promoter could produce biologically active protein, but the levels produced in murine cells were 10-50-fold lower than those produced in human cells (Addison et al., 1995 a, b) . To determine whether the higher level of expression in human cells was due to a species preference of the promoter, or due to a greater efficiency of infection of human cells by the human Ad 5-based vectors, we cloned the murine CMV (MCMV) IE promoter (Dorsch-Hasler et al., 1985) into our vectors and The coding sequences for β-gal were cloned into the shuttle plasmids pCA4, pCA14, pMH4 or pMH5, and the resulting plasmids, pCA12, pCA17, pCA36 and pCA35 respectively, were used to generate the viruses used in this study. All four plasmids contain Ad sequences from m.u. 0-1 (nucleotides 22-341) and from 9.8-16.1 (nucleotides 3525-5790), with a polycloning site and the SV40 polyadenylation signal inserted between the two segments of the Ad left end genomic sequences. In addition, pCA4 and pCA14 carry the HCMV promoter from k299 to j72 relative to the transcriptional start. pMH4 and pMH5 are derivatives of pCA14 in which two different fragments of the MCMV promoter from k491 to j36 (pMH4) or from k1336 to j36 (pMH5) replace the HCMV promoter. Expression of lacZ is directed rightwards (parallel to E1) in pCA17, pCA36 and pCA35, while it is directed leftwards (anti-parallel to E1) in pCA12. Similar constructs containing the luciferase cDNA in place of the lacZ sequences were also constructed, generating pCA18, pDK1 and pDK2 (rightwards directed) or pCA15 (leftwards directed). (B) Recombinant Ad vectors. Each of the plasmids described in (A) was cotransfected with either pJM17 (McGrory et al., 1988) or pBHG10 (Bett et al., 1994) to generate replication deficient adenoviral vectors. The viruses used in this study all possess the E. coli lacZ gene under control of the HCMV IE (AdCA12lacZ or AdCA17lacZ), a 1n4 kb MCMV IE (AdCA35lacZ) or a 0n5 kb MCMV IE (AdCA36lacZ) promoter. The vectors AdCA15luc, AdCA18luc, AdDK2 and AdDK1 resemble AdCA12lacZ, AdCA17lacZ, AdCA35lacZ and AdCA36lacZ respectively, except the cDNA for firefly luciferase replaces the lacZ gene within the transgene expression cassettes. Solid arrows represent the inverted terminal repeats of the adenoviral genome, the shaded arrows represent the HCMV IE or the MCMV IE promoters, the solid bar represents the SV40 polyadenylation signal, and the shaded bar represents the lacZ sequence or the firefly luciferase cDNA.
examined expression levels versus the HCMV IE promoter. The MCMV IE promoter contains imperfect repeat elements similar to the HCMV promoter, and is believed to bind some of the same transcription factors (Dorsch-Hasler et al., 1985) . We found that the murine viral promoter element consistently expressed as well as, or better than, the HCMV IE promoter in all cell types examined, without the pronounced relative decrease in expression in rodent cells compared to human cells, as is observed for the HCMV IE promoter. This observation is of great importance since the majority of preclinical studies in gene therapy are initially performed in rodent models. Our results suggest that Ad vectors incorporating the MCMV IE, instead of the HCMV IE promoter, should express transgene products in animal models at levels that more closely approximate levels expected in human tissue.
Methods
Cell lines. All viruses were propagated in human 293 cells (Graham et al., 1977) , which express the Ad5 early region 1 (E1) proteins. Other cell lines used include : MRC5 human fibroblasts (ATCC CCL 171), 983M human melanoma cells (Herlyn et al., 1985) (kindly provided by N. Lassam, Sunnybrook Hospital, Toronto, Ontario, Canada), MDCK canine kidney cells (ATCC CCL 34), RF cultured rat lung fibroblasts isolated from Sprague-Dawley rats, B16BL6 murine melanoma cells (Fidler, 1975) , P815 murine mastocytoma cells (ATCC CRL 6448), SV329 SV40 transformed murine kidney cells and MT1A2 murine mammary adenocarcinoma cells derived from transgenic mice expressing polyomavirus middle T antigen (PyMidT) (Guy et al., 1992) . The 293 and MT1A2 cell lines were grown in modified Eagle's medium (MEM) ; MRC5, MDCK, RF and SV329 cells were grown in α-MEM ; B16BL6 cells were grown in MEM supplemented with non-essential amino acids (0n1 mM) and sodium pyruvate (1 mM) ; and 983M and P815 cells were grown in RPMI. All media were enriched with -glutamine (2 mM), penicillin (100 U\ml), streptomycin (0n1 mg\ml), fungizone (2n5 µg\ml) and 10 % foetal bovine serum. Culture media and supplements, with the exception of fungizone (Squibb Canada), were obtained from Gibco BRL.
Construction of recombinant viruses. The pCA4 and pCA14 shuttle plasmids contain the Ad5 genomic sequences from map units (m.u.) 0 to 15.8 with E1 sequences between m.u. 1 and 9.8 replaced by the HCMV IE promoter (from nucleotides k299 to j72 relative to transcriptional start ; gift of Gavin Wilkinson, PHLS, CAMR, Porton Down, Salisbury, UK), a polycloning region, and the SV40 polyadenylation signal (An). In pCA14, the expression cassette is oriented parallel to the direction of E1 transcription (rightwards with respect to the conventional map of the adenoviral genome), whereas in pCA4, the expression cassette is in an anti-parallel orientation ( Fig. 1 A) . pCA12 was constructed by inserting an XbaI-SalI fragment from pAB16lacZ (Bett, 1995) , containing the lacZ gene, into pCA4 (Hitt et al., 1995) . AdCA12lacZ viral vector was obtained by cotransfection of 293 cells with pCA12 and pJM17 (McGrory et al., 1988) , as previously described (Hitt et al., 1995) . pCA17 was constructed by inserting the lacZ gene into the polycloning site of pCA14 (Hitt et al., 1995) , and was then recombined with pJM17 in 293 cells to generate AdCA17lacZ. The plasmids pCA15 and pCA18 were derived from pCA4 and pCA14, respectively, and contain the cDNA sequence of the firefly luciferase gene from pSVOAL (DeWet et al., 1987 , gift of D. R. Helinski, University of California, San Diego, La Jolla, Calif., USA) flanked by BamHI restriction sites. The cDNA for human IL-2 (gift of Robert Ralston, Chiron Corporation, Emeryville, Calif., USA) was cloned into pCA4 and pCA14 generating pCAIL-2AP and pCAIL-2P respectively. Cotransfection of these plasmids with pJM17 in 293 cells yielded the recombinant vectors AdCA15luc, AdCA18luc, AdCAIL-2AP and AdCAIL-2P.
The shuttle plasmids pMH4 and pMH5 resemble pCA14 in structure except that the HCMV IE promoter was replaced by a 0n5 kb (k491 to j36) or a 1n4 kb (k1336 to j36) fragment of the MCMV IE promoter from pHind33 (Dorsch-Hasler et al., 1985 ; gift of U. Koszinowski, Institute for Medical Virology, University of Heidelberg, Germany), respectively. The lacZ reporter gene was placed under control of the MCMV IE promoter by inserting the 3n1 kb XbaI-SalI fragment from pCA17 into pMH4 and pMH5, generating pCA36 and pCA35, respectively. The luciferase gene was cloned into the unique BamHI site of pMH4 and pMH5 generating pDK1 and pDK2, respectively. Recombinant viruses were isolated following cotransfection of pCA36, pCA35, pDK1 or pDK2 with pBHG10 (Bett et al., 1994) in 293 cells yielding AdCA36lacZ (0n5 kb MCMV IE), AdCA35lacZ (1n4 kb MCMV IE), AdDK1 (0n5 kb MCMV IE) and AdDK2 (1n4 kb MCMV IE), respectively ( Fig. 1 B) . The recombinant virus AdCA38lacZ was generated following cotransfection and homologous recombination in 293 cells of the plasmids pBHG10 and pCA38. Plasmid pCA38 is a derivative of pCA17, where an HCMV IE promoter fragment from pMA1 [from nucleotides k760 to j54 relative to transcriptional start (Anton & Graham, 1995) ] replaces the smaller HCMV IE promoter. The genomic structure of all viral constructs was confirmed by restriction enzyme digestion and gel electrophoresis. Recombinant vectors were plaque purified, and grown to high titre in 293 cells, as previously described (Hitt et al., 1995) . Crude lysates of infected 293 cells were used for all in vitro experiments, while caesium chloride banded virus was used for in vivo experiments.
β-Galactosidase assays. Cell monolayers were infected at an m.o.i. of 10 p.f.u. per cell and, at various times post-infection, cells were scraped into the medium, centrifuged at 2000 g for 5 min, and stored at k70 mC until assayed, when cell pellets were resuspended in 200 µl of reporter lysis buffer (Promega). After a 15 min incubation at room temperature, the lysates were centrifuged at 2500 g for 5 min to pellet debris. Serial dilutions of the cell extracts were prepared in lysis buffer, and 40 µl of each dilution was assayed for β-galactosidase (β-gal) activity according to standard methods using o-nitrophenol β--galactopyranoside (Sambrook et al., 1989) . The amount of β-gal present was estimated by comparison with a standard curve derived from known amounts of β-gal protein (Boehringer Mannheim). All results were normalized to 10' infected cells.
Luciferase assays. To determine luciferase activity, monolayers of near confluent cells were infected at an m.o.i. of 10. At various times postinfection, cells were harvested, and assayed as previously described (Mittal et al., 1993) . The amount of luciferase in the samples was calculated from a standard curve obtained using known amounts of purified luciferase protein (Boehringer Mannheim).
Interleukin-2 assays. Cell monolayers were infected with AdCAIL-2P or AdCAIL-2AP at an m.o.i. of 10, and at various times postinfection, infected cell supernatants were removed and stored at k70 mC. The amount of IL-2 present in each sample was determined by ELISA using the human IL-2 ELISA kit from R&D Systems, according to the manufacturer's protocol.
Northern blot analysis. MRC5 or SV329 cells were infected at an m.o.i. of 10, and 48 h later the cells were scraped into RLU lysis buffer (Qiagen) and stored at k70 mC. Total RNA was extracted using the RNeasy kit (Qiagen) according to the manufacturer's protocol. For Northern blot analysis, equal quantities of total RNA were separated by formaldehyde-agarose gel electrophoresis and transferred to a positively charged nylon membrane (Boehringer Mannheim), by capillary transfer (Sambrook et al., 1989) . lacZ probes were generated by random primelabelling of a DNA fragment containing the lacZ cDNA using the Digoxigenin (DIG) High Prime Labelling Kit (Boehringer Mannheim). A commercially available DIG-labelled RNA probe to human β-actin was used as an internal control (Boehringer Mannheim). Hybridization of the nylon membrane and chemiluminescent detection of the bound DIGlabelled probe were performed according to the manufacturer's protocol.
Detection of luciferase produced in vivo. For detection of luciferase produced in vivo, animals were injected intratumorally with 1i10) p.f.u. of AdCA18luc (HCMV IE) or AdDK1 (0n5 kb MCMV IE) and 48 h post-injection tumours were removed from animals and snap frozen in liquid nitrogen. Tissue was subsequently homogenized in buffer (0n1 M potassium phosphate pH 7n8, 1 mM PMSF and 10 µg\ml aprotinin) with a Tekmarr Tissuemizer, sonicated and centrifuged to remove debris. The homogenates were then immediately assayed for luciferase activity as previously described (Mittal et al., 1993) .
Results

Effect of orientation on gene expression
The lacZ gene was cloned into a series of shuttle plasmids containing either the HCMV IE promoter (k299 to j72) or one of two forms of the MCMV IE promoter (k1336 to j36 or k491 to j36) (Fig. 1 A) and the resulting plasmids were used to generate a series of recombinant Ad vectors (Fig. 1 B) as described in Methods. Initially, we compared expression of lacZ under the control of the HCMV IE promoter inserted in the right to left (i.e. anti-parallel to the direction of E1 transcription, AdCA12lacZ), versus left to right orientation (i.e. parallel to the direction of E1 transcription, AdCA17lacZ) in a recombinant Ad vector. Human MRC5 fibroblast cells were infected at an m.o.i. of 10, harvested at 24 h intervals, and assayed for β-gal activity. AdCA17lacZ produced 7-fold higher levels of β-gal than did AdCA12lacZ (Table 1) . Similar virus constructs encoding either the luciferase reporter gene or the human IL-2 cDNA also showed increased expression when the cassette was inserted in the rightwards orientation (Table 1) . This orientation dependent difference was also noted in a variety of other human and murine cell types (data not shown).
HCMV IE driven expression in various cell types
AdCA17lacZ was chosen for further analysis to determine the level of lacZ expression in different cell types. Several murine and human cell lines were infected at an m.o.i. of 10, 
* R, rightwards ; L, leftwards (with respect to the Ad genome). † Cells were infected, harvested and assayed for β-gal, luciferase or IL-2 activity as described in Methods. Expression levels shown are those measured at 48 h post-infection. ‡ The fold increase is the increase in the quantity of protein produced by cells infected with viruses driving expression rightwards relative to leftwards. Fig. 2 . Expression of the lacZ reporter gene under control of the HCMV IE promoter in murine and human cells. Cells were infected at an m.o.i. of 10 p.f.u. per cell and pellets were harvested daily and assayed for β-gal activity as described in Methods. The murine cell lines used were P815 mastocytoma, and B16BL6 melanoma, and the human cells used were 983M melanoma and the MRC5 fibroblast strain.
and the cells were harvested at 24 h intervals for β-gal assays.
Up to 100 µg of β-gal per 10' cells was detected following infection of human cells with AdCA12lacZ (Fig. 2) . Murine cell lines produced approximately 10-100-fold lower levels of β-gal than human cells and similar differences were observed with other reporter genes (data not shown). Nonetheless, several hundred nanograms of β-gal were produced per 10' infected murine cells by day 3 post-infection, from the HCMV IE construct.
Examination of promoter specificity
The consistently low expression observed in murine cells compared to human cells could be due to species preferences associated with the HCMV IE promoter or to inefficient infection of rodent cells by a human adenovirus. To determine if the difference in expression observed in cells of different species was due, at least in part, to reduced promoter activity, two viruses were constructed which expressed lacZ under the control of the MCMV IE promoter in a rightwards orientation. One vector contained a larger MCMV IE enhancer\promoter region (from k1336 to j36, AdCA35lacZ) and the other contained a smaller fragment (from k491 to j36, AdCA36lacZ). The promoter activity of these two recombinant viruses was compared to that obtained from AdCA17lacZ. A variety of cell types from species which might be used as models for gene therapy studies, including human, murine, rat, canine and monkey cells, were infected with the above viruses, and the level of lacZ expression was determined. In human MRC5 cells, both MCMV IE promoters produced levels of β-gal protein about 2-fold greater than observed for the HCMV IE promoter over a period of 4 days (Fig. 3 A) . In contrast, in human 983M melanoma cells, the MCMV IE promoters were significantly more effective than HCMV IE in driving expression of β-gal, resulting in 15-30-fold higher levels (Fig. 3 B) . In two murine cell lines, MT1A2 and SV329, both MCMV IE promoters induced β-gal expression at least 6-fold and 22-fold more efficiently than the HCMV IE promoter (Fig. 3 C, D) . The 1n4 kb MCMV IE promoter expressed 2-4-fold greater amounts of β-gal than the HCMV IE promoter in canine MDCK cells (Fig. 3 E) and primary canine osteosarcoma cells (data not shown), and 4-5-fold better in RF rat lung fibroblasts (Fig. 3 F) . In addition, the 1n4 kb MCMV IE promoter expressed 4-5-fold higher than the HCMV IE promoter in two monkey cell lines, LLC-MK # (ATCC CCL 7) and BS-C-1 (ATCC CCL 26) (A. J. Bett, C. L. Addison & F. L. Graham, unpublished data) . The increase in expression driven by MCMV IE compared to HCMV IE was also noted for the Ad vectors containing the luciferase reporter gene (Table 2) . No consistent differences were observed between the expression of lacZ driven by the 1n4 kb and that driven by the 0n5 kb MCMV IE promoter in any of the cell lines tested, indicating that the smaller fragment was sufficient to obtain high levels of expression. In summary, we found that in all cell types examined, transgene expression driven by either the small or large MCMV IE promoter was as good as, and frequently several fold better than, that of the HCMV IE promoter in vitro.
Analysis of HCMV IE and MCMV IE derived transcripts
Higher β-gal levels in cells infected with MCMV IE promoted compared to HCMV IE promoted vectors could be caused by increased levels of transcription or increased efficiency of translation. To distinguish between these two possibilities, Northern analysis was performed to determine the quantity of lacZ transcript present. Human MRC5 or murine SV329 cells were infected with either the HCMV IE (AdCA17lacZ) or the MCMV IE (AdCA35lacZ and AdCA36lacZ) promoter constructs. Two bands at approximately 3n3 kb and 3n8 kb were visible upon hybridization with a lacZ probe (Fig. 4) . The 3n3 kb transcript was the predominant transcript, and is likely the result of transcriptional termination at the SV40 An site in the expression cassette. Because the vector backbone retains the E1b polyadenylation signals downstream of the expression cassette, termination at this second An site would give rise to a fragment of 3n8 kb; however, this appears to occur at a reduced frequency compared to termination at the SV40 polyadenylation site as indicated by the reduced intensity of the 3n8 kb band (Fig. 4) . In both human and mouse cells, the MCMV IE promoter (either large or small fragment) directed a higher level of transcription than the HCMV IE promoter, in agreement with Fig. 4 . Northern blot analysis of lacZ transcripts produced by infected human or murine cells. MRC5 human fibroblasts or SV329 murine epithelial cells were either mock infected or infected at an m.o.i. of 10 p.f.u. per cell with either AdCA17lacZ (HCMV IE), AdCA35lacZ (1n4 kb MCMV IE) or AdCA36lacZ (0n5 kb MCMV IE). Cells were harvested 48 h post-infection and RNA was isolated as described in Methods. Equal amounts of total RNA were subjected to formaldehyde-agarose gel electrophoresis, and were transferred to positively charged nylon membranes by capillary transfer. Specific lacZ and β-actin transcripts were visualized using the chemiluminescent DIG detection system (Boehringer Mannheim) as described in Methods, and subsequent exposure to Kodak X-AR film.
the differences observed in protein levels. Because the genes were all cloned in a similar manner [i.e. identical Kozak sequences (Kozak, 1991) were present at the translational start site, and identical polyadenylation signals 3h of the coding sequences], differences in protein levels are most likely due to differences in the rate of transcription or stability of the transcripts rather than differences in the efficiency of translation.
In vivo expression of luciferase and β-gal
For comparison of in vivo expression levels from the HCMV IE and MCMV IE promoters, we injected 1i10) p.f.u. of AdCA18luc (HCMV IE) or AdDK1 (0n5 kb MCMV IE) intratumorally in animals bearing subcutaneous PyMidT induced tumours . At 48 h postinjection, tumours were removed, snap frozen in liquid nitrogen, and lysates were prepared as described in Methods. Approximately 7-fold more luciferase was detected in animals injected with AdDK1 compared to AdCA18luc [9n3p3n8i10' relative light units (RLU) per tumour compared to 1n4p0n7i10' RLU per tumour, respectively]. Intratumoral injection of vectors expressing β-gal under control of the HCMV IE promoter (AdCA17lacZ) or the 1n4 kb MCMV IE promoter (AdCA35lacZ) was also performed, and β-gal was detected by immunostaining of paraffin embedded tissue sections. The number of positively stained cells, and the intensity of staining, was significantly greater in the MCMV IE vector compared to the HCMV IE vector injected tumour (data not shown). These data are in agreement with previous results obtained in vitro (see MT1A2 cell line in Fig. 3 D) , and suggest that the MCMV IE promoter may direct increased levels of expression in vivo as well as in vitro.
Comparison of a larger fragment of the HCMV IE promoter to the MCMV IE promoters
The fragment of the HCMV IE promoter from k299 to j72 was selected for these studies since it had been shown to induce high levels of transgene expression in human cells, and its reduced size allowed for the insertion of larger genes into the Ad vector backbones. Compared to the full-length HCMV IE enhancer, however, this fragment has fewer repeats of the DNA sequence motifs required for transcription factor binding. Therefore, we examined the ability of a 0n8 kb HCMV IE promoter fragment (k760 to j54) in an Ad vector to drive transgene expression in murine cells. Following infection of SV329 murine cells with an Ad vector expressing lacZ under control of this larger HCMV IE promoter (AdCA38lacZ), we detected a 3-fold increase in the amount of β-gal protein when compared to the small HCMV IE promoted vector (AdCA17lacZ). This level of expression, however, was still 4-fold lower than that obtained following infection of cells with the Ad vector expressing lacZ under control of the 0n5 kb MCMV IE promoter (AdCA36lacZ). Similar trends were observed in other cell types including the canine MDCK cells, murine MT1A2 cells and 983M human melanoma cells. We found that the only cell type in which the large HCMV IE promoted construct expressed higher than the small MCMV IE promoted construct was the human MRC5 fibroblast cell strain (2-fold higher). These data indicate that although the use of a 0n8 kb fragment of the HCMV IE promoter can result in higher levels of expression compared to the 0n4 kb HCMV IE promoter fragment, the MCMV IE promoter still outperformed the HCMV IE promoter in cells of murine origin.
Discussion
A major goal in the development of Ad vectors is the production of efficient gene delivery systems for gene therapy applications. There are several criteria which must be met for such systems to be widely useful, among them : (1) procedures for inserting the transgene into the vector must be relatively simple, (2) the vector system should have a relatively large cloning capacity to accommodate a variety of foreign gene inserts, and (3) once rescued into recombinant virus, the transgene must be expressed in both humans and animal models at clinically relevant levels. We and others have previously described adenovirus based vector systems which to a large extent fulfil these criteria (Parks et al., 1996 ; Gerard & Meidell, 1995 ; Hitt et al., 1995 ; Bett et al., 1994 ; Engelhardt et al., 1994) . Most of the E1 replacement vectors generated in our laboratory carry rightward oriented expression cassettes based on the HCMV IE enhancer\promoter sequence (k299 to j72) for high level expression in a variety of cell types. Although we have found this system satisfactory for expression of a number of transgenes in animal models [e.g. intratumoral expression of cytokines by recombinant Ad vectors in a mouse model for breast cancer (Bramson et al., 1996 a, b ; Addison et al., 1995 a, b) ], for some applications the level of transgene expression may be insufficient to induce the desired response in animals. Furthermore, to extrapolate results of studies in animal models to clinical applications, it is preferable that expression levels be comparable in human and rodent cells.
We observed that transgene expression was affected by the orientation of the expression cassette relative to sequences in the Ad vector backbone : expression cassettes directed rightward (i.e. parallel to the direction of E1 transcription) expressed higher levels of protein. Xu et al. (1995) , noted the same orientation dependence using E1 replacement Ad vectors expressing rotavirus antigen VP7sc regulated by the 0n4 kb HCMV IE promoter or the Ad 2 major late promoter. This effect may be due, in part, to the presence of the E1a enhancer which remains in the vector backbone. It is conceivable that in the rightwards oriented recombinants, transcription factors binding to the E1a enhancer may act synergistically with those binding the HCMV IE enhancer sequences.
The cell type and species preferences we have observed may reflect a property of HCMV itself. HCMV has a relatively narrow host range for productive infection and does not replicate efficiently in transformed human cells, being restricted mostly to human diploid fibroblasts (Stamminger et al., 1990 ; Stinski, 1990) . Recent studies on the ability of HCMV and MCMV to infect and replicate in cells of various species have shown that MCMV has a much wider host cell range than HCMV and can replicate in murine, simian and human cells (Lafemina et al., 1988) . The block in HCMV replication in nonhuman cells correlates with reduced levels of transcription of the major IE gene (Nelson & Groudine, 1986) . It is possible that expression driven by the HCMV IE promoter within an Ad vector is subjected to the same host restriction found for HCMV replication. Recent studies using the HCMV IE promoter for transgene expression in transgenic mice [including one which used an HCMV IE promoter fragment similar to the one used in our studies, i.e. k302 to j72 (Kothary et al., 1991) ], indicated that the HCMV IE promoter expressed in a tissue and cell specific pattern (Baskar et al., 1996 a, b ; Kothary et al., 1991) , and the majority of expression occurred in tissues that are naturally infected by HCMV (Baskar et al., 1996 b) . This finding suggests a role for tissuespecific factors that bind the viral promoter elements and contribute to the variation in the levels of transgene expression.
To examine the possibility of species preferences of the CMV IE promoters in Ad vectors, we constructed Ad vectors containing lacZ or the luciferase gene under the control of either the MCMV or HCMV IE promoter. We found the activity of the MCMV IE promoter to be consistently higher than the HCMV IE promoter in murine cells and equal to or higher than the HCMV IE promoter in all other cell types examined. We have also observed that in vivo the MCMV IE promoter directs higher levels of transgene expression than the HCMV IE promoter. This observation has also been made by others using the AdCA17lacZ and AdCA35lacZ vectors, where expression from the MCMV IE promoter following intraocular vector injection was higher and persisted longer in rat intraocular tissue (K. Csaky, personal communication).
Our studies indicate that Ad vectors containing the MCMV IE promoter express much more efficiently in rodent cells than do vectors containing the HCMV IE promoter, although the absolute levels of transgene product detected in murine cells were still slightly lower than those produced in human cells. It is possible that Ad vectors do not infect murine cells as efficiently as human cells due to the lack of Ad5 specific cell receptors ; however, within each cell line, the different Ad vectors would infect with equal efficiency (since they all contain identical structural proteins), and thus differences in promoter activity seen in infected cells are not due to differences in vector infection.
To construct vectors which will be efficacious as vehicles for gene delivery, it is important to choose a system which results in a high degree of cell transduction and appropriate levels of foreign gene expression. Ad vectors can infect replicating and non-replicating cells yielding a very high degree of cell transduction. One of the drawbacks of Ad vectors for gene therapy is the anti-viral immune response associated with their administration in vivo (Yang et al., 1994) . This anti-viral immunity limits the duration of expression and effectiveness of the transgene following a second administration of the vector. If the level of transgene expression is low, it may require the administration of greater amounts of vector in order to attain therapeutic levels of transgene product, and may result in stronger anti-viral immune responses, further limiting transgene expression. By maximizing expression levels, e.g. through the use of strong promoters, one can minimize the amount of vector required to achieve high levels of the transgene, possibly prolonging transgene expression and allowing vector readministration. We and others have found that the HCMV IE promoter can direct expression of very high levels of transgene, but as reported here, these levels are reduced in rodent compared to human cells. The HCMV IE promoter also appears to be more subject to species and cell type specificity than the MCMV IE promoter. Our data suggest that the MCMV IE promoter results in expression levels which rival that of the HCMV IE promoter in human cells, and outperforms it in cells of murine and rat origin. We suggest that the use of the murine rather than the human CMV IE promoter to drive transgene expression would provide results in animal models that could be more readily extrapolated to a clinical setting.
